Dr. Hoenle AG (DE:HNL)
XETRA:HNL
Top Page
Dr. Hoenle AG
(XETRA:HNL)
Select Model
Select Model
Rating:54Neutral
Price Target:
€9.00
▲(26.76% Upside)
Action:ReiteratedDate:03/06/26
The score is driven primarily by improving but still unprofitable financial performance (ongoing net loss despite revenue growth and positive cash flow). Technicals add moderate support with price above key moving averages and a positive MACD, while valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Free Cash Flow Generation
Consistent positive operating and free cash flow provide durable internal funding for working capital, product development and selective capex. This reduces reliance on external financing, improves resilience through industry cycles, and supports reinvestment into recurring after‑sales and measurement offerings.
Negative Factors
Persistent Net Losses
Ongoing net losses and negative operating income indicate the company has not yet converted revenue growth into sustainable profits. Continued losses constrain retained earnings, limit R&D/marketing budgets, and may force reliance on external capital if cash generation weakens.
Read all positive and negative factors
Positive Factors
Negative Factors
Free Cash Flow Generation
Consistent positive operating and free cash flow provide durable internal funding for working capital, product development and selective capex. This reduces reliance on external financing, improves resilience through industry cycles, and supports reinvestment into recurring after‑sales and measurement offerings.
Read all positive factors
Dr. Hoenle AG (HNL) vs. iShares MSCI Germany ETF (EWG)
Market Cap
€53.10M
Dividend YieldN/A
Average Volume (3M)6.13K
Price to Earnings (P/E)―
Beta (1Y)0.76
Revenue Growth-2.20%
EPS Growth-153.32%
CountryDE
Employees585
SectorGeneral
Sector StrengthN/A
IndustryElectrical Equipment & Parts
Share Statistics
EPS (TTM)-0.25
Shares Outstanding6,062,930
10 Day Avg. Volume3,193
30 Day Avg. Volume6,130
Financial Highlights & Ratios
PEG Ratio0.21
Price to Book (P/B)0.65
Price to Sales (P/S)0.53
P/FCF Ratio15.82
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.03
Revenue Forecast (FY)€100.27M
Dr. Hoenle AG Business Overview & Revenue Model
Company Description
Dr. Hönle AG supplies industrial UV technologies and systems in Germany and internationally. The company operates through three segments: Adhesives, Equipment & Systems, and Glass & Lamps. The Adhesives segment provides industrial adhesives for ap...
How the Company Makes Money
Dr. Hönle AG primarily makes money by selling industrial UV and LED-UV equipment and the associated recurring components and services required to operate them. Key revenue streams include: (1) Sales of UV curing systems used in industrial producti...
Dr. Hoenle AG Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
56
Neutral
Cash Flow
63
Positive
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 93.75M | 93.68M | 98.73M | 106.34M | 116.09M | 115.17M |
| Gross Profit | 12.43M | 12.47M | 60.07M | 53.35M | 69.28M | 69.34M |
| EBITDA | 5.42M | 6.00M | 3.02M | 539.00K | 20.41M | 14.02M |
| Net Income | -4.11M | -3.17M | -13.28M | -11.01M | -13.36M | -4.82M |
Balance Sheet | ||||||
| Total Assets | 142.00M | 145.52M | 155.38M | 176.16M | 195.46M | 202.91M |
| Cash, Cash Equivalents and Short-Term Investments | 6.71M | 7.75M | 7.51M | 9.32M | 7.13M | 12.07M |
| Total Debt | 47.80M | 48.25M | 53.24M | 56.89M | 59.53M | 53.64M |
| Total Liabilities | 66.31M | 68.48M | 75.70M | 80.02M | 88.22M | 91.78M |
| Stockholders Equity | 75.54M | 76.87M | 79.42M | 95.82M | 106.88M | 110.72M |
Cash Flow | ||||||
| Free Cash Flow | 3.20M | 3.17M | 3.44M | 209.00K | -11.71M | -15.96M |
| Operating Cash Flow | 5.16M | 5.06M | 5.53M | 3.14M | -7.41M | 1.13M |
| Investing Cash Flow | 1.40M | 1.49M | -2.37M | 2.65M | -1.69M | -24.50M |
| Financing Cash Flow | -7.41M | -6.44M | -4.90M | -3.42M | 3.73M | 1.25M |
Dr. Hoenle AG Technical Analysis
Positive
7.10
Price Trends
9.08
Negative
8.22
Positive
8.41
Positive
Market Momentum
-0.23
Positive
48.68
Neutral
63.79
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DE:HNL, the sentiment is Positive. The current price of 7.1 is below the 20-day moving average (MA) of 8.94, below the 50-day MA of 9.08, and below the 200-day MA of 8.41, indicating a neutral trend. The MACD of -0.23 indicates Positive momentum. The RSI at 48.68 is Neutral, neither overbought nor oversold. The STOCH value of 63.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for DE:HNL.
Dr. Hoenle AG Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
70 Outperform | €967.25M | 15.83 | 18.05% | 0.78% | 34.77% | 52.20% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | €185.59M | -37.36 | -2.41% | ― | -1.42% | -99.55% | |
54 Neutral | €53.10M | -6.85 | -5.31% | ― | -2.20% | -153.32% | |
52 Neutral | €163.88M | -3.68 | -16.86% | ― | -1.24% | 41.31% | |
49 Neutral | €28.56M | -2.43 | 10.78% | ― | -6.99% | 10.97% |
* General Sector Average
DE:HNL
Dr. Hoenle AG
8.76
0.30
3.55%
DE:LPK
LPKF Laser & Electronics
6.69
-1.31
-16.37%
DE:M5Z
Manz AG
0.08
-0.22
-73.33%
DE:MXHN
MAX Automation
4.50
-1.34
-22.95%
DE:SNG
Singulus Technologies
3.21
1.56
94.55%
DE:SMHN
Suss Microtec
50.60
21.31
72.75%
Dr. Hoenle AG Corporate Events
Business Operations and StrategyExecutive/Board Changes
Hoenle AG Confirms CEO Franz Richter as Management Board Chairman to Drive Profit Turnaround
Positive
Feb 2, 2026
Hoenle AG has strengthened its top management by confirming Dr. Franz Richter as a member and chairman of the Management Board for a three-year term, extending his contract as CEO until February 28, 2029. Having already taken over the CEO role on ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.